NxStage Medical, Inc. (NASDAQ:NXTM) was downgraded by stock analysts at William Blair from an “outperform” rating to a “market perform” rating in a research report issued on Monday.

Several other research analysts also recently weighed in on NXTM. Northland Securities downgraded NxStage Medical from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 4th. Canaccord Genuity reiterated a “buy” rating and issued a $32.00 target price on shares of NxStage Medical in a research note on Monday, May 8th. BTIG Research reiterated a “buy” rating and issued a $27.00 target price on shares of NxStage Medical in a research note on Wednesday, May 10th. Jefferies Group LLC lowered their target price on NxStage Medical from $38.00 to $33.00 and set a “buy” rating on the stock in a research note on Wednesday, May 10th. Finally, Craig Hallum started coverage on NxStage Medical in a research note on Tuesday, June 27th. They issued a “buy” rating and a $32.00 target price on the stock. One analyst has rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $29.67.

NxStage Medical (NXTM) opened at 29.67 on Monday. The firm’s market capitalization is $1.95 billion. NxStage Medical has a one year low of $20.45 and a one year high of $30.80. The firm has a 50-day moving average price of $24.08 and a 200-day moving average price of $25.81.

NxStage Medical (NASDAQ:NXTM) last released its quarterly earnings results on Monday, August 7th. The medical device company reported ($0.03) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.03). NxStage Medical had a negative return on equity of 2.31% and a negative net margin of 1.25%. The firm had revenue of $92.20 million for the quarter, compared to the consensus estimate of $96.47 million. During the same quarter last year, the business posted ($0.03) EPS. The firm’s quarterly revenue was up .0% compared to the same quarter last year. Equities analysts anticipate that NxStage Medical will post ($0.03) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This story was first posted by American Banking News and is the property of of American Banking News. If you are accessing this story on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/08/08/nxstage-medical-inc-nxtm-stock-rating-lowered-by-william-blair.html.

In related news, SVP Winifred L. Swan sold 3,500 shares of NxStage Medical stock in a transaction on Monday, May 15th. The stock was sold at an average price of $21.94, for a total transaction of $76,790.00. Following the completion of the transaction, the senior vice president now directly owns 17,770 shares of the company’s stock, valued at $389,873.80. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Matthew W. Towse sold 4,300 shares of NxStage Medical stock in a transaction on Monday, May 22nd. The stock was sold at an average price of $21.36, for a total value of $91,848.00. Following the transaction, the senior vice president now directly owns 29,637 shares of the company’s stock, valued at $633,046.32. The disclosure for this sale can be found here. Insiders sold a total of 29,150 shares of company stock valued at $669,351 over the last three months. Insiders own 4.70% of the company’s stock.

A number of institutional investors have recently modified their holdings of NXTM. FMR LLC boosted its position in shares of NxStage Medical by 1.9% in the first quarter. FMR LLC now owns 7,482,201 shares of the medical device company’s stock valued at $200,747,000 after buying an additional 137,399 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of NxStage Medical by 8.5% in the first quarter. Vanguard Group Inc. now owns 5,273,762 shares of the medical device company’s stock valued at $141,495,000 after buying an additional 412,233 shares in the last quarter. BlackRock Inc. boosted its position in shares of NxStage Medical by 38,360.4% in the first quarter. BlackRock Inc. now owns 4,413,326 shares of the medical device company’s stock valued at $118,408,000 after buying an additional 4,401,851 shares in the last quarter. Eagle Asset Management Inc. purchased a new position in shares of NxStage Medical during the first quarter valued at about $54,558,000. Finally, William Blair Investment Management LLC boosted its position in shares of NxStage Medical by 491.6% in the second quarter. William Blair Investment Management LLC now owns 1,959,318 shares of the medical device company’s stock valued at $49,120,000 after buying an additional 1,628,114 shares in the last quarter. 91.11% of the stock is owned by hedge funds and other institutional investors.

About NxStage Medical

NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.

Analyst Recommendations for NxStage Medical (NASDAQ:NXTM)

Receive News & Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.